Ventrus Biosciences Revenue, Profits - ASMB Quarterly Income Statement

Add to My Stocks
$45.71 $2.02 (4.23%) ASMB stock closing price Jun 21, 2018 (Closing)

ASMB stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Ventrus Biosciences stock price. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the ASMB stock is bound to reflect the impact of the QOQ growth of 7.53%. One also needs to look at Ventrus Biosciences assets, operating expenses and Ventrus Biosciences free cash flow. The Ventrus Biosciences profit and loss statement shows revenue of $3.57M for 2018 Q1. Revenue has grown by 7.53% QoQ for ASMB stock.

View and download details of revenue and profits for Ventrus Biosciences for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Ventrus Biosciences Revenues or Net Sales
3.57M3.32M2.66M2.36M------
Cost Of Goods Sold (COGS)----------
Ventrus Biosciences Gross Profit
3.56M3.33M2.65M2.35M------
Research & Development Expense14.54M10.61M10.92M12.12M10.57M8.64M8.83M7.51M8.11M5.23M
Selling General & Admin Expense5.69M5M4.18M3.8M4.04M3.26M2.84M2.93M3.15M2.96M
Income Before Depreciation Depletion Amortization-16.67M-12.29M-12.45M-13.56M-13.92M-11.88M-11.67M-10.45M-11.27M-8.18M
Depreciation Depletion Amortization----------
Non Operating Income----0.1M--0.29M----
Interest Expense----------
Ventrus Biosciences Pretax Income
-16.24M-11.96M-12.3M-13.66M-13.93M-12.17M-11.57M-10.15M-10.98M-7.76M
Provision for Income Taxes--8.96M-0.03M-0.06M--0.61M----
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-16.25M-3.01M-12.27M-13.6M-13.93M-11.55M-11.57M-10.15M-10.99M-7.36M
Extraordinary Items & Discontinued Operations----------
Ventrus Biosciences Profit/ Loss (Net Income)
-16.25M-3.01M-12.27M-13.6M-13.93M-11.55M-11.57M-10.15M-10.99M-7.36M
Average Shares used to compute Diluted EPS20.23M18.79M17.37M17.34M17.27M17.23M17.23M17.23M17.23M15.7M
Average Shares used to compute Basic EPS20.23M18.79M17.37M17.34M17.27M17.23M17.23M17.23M17.23M15.7M
Income Before Nonrecurring Items-16.25M-3.01M-12.27M-13.6M-13.93M-11.55M-11.57M-10.15M-10.99M-7.36M
Income from Nonrecurring Items----------
Ventrus Biosciences Earnings Per Share Basic Net
-0.80-0.16-0.71-0.78-0.81-0.67-0.67-0.59-0.64-0.45
Ventrus Biosciences Earnings Per Share Diluted Net
-0.80-0.16-0.71-0.78-0.81-0.67-0.67-0.59-0.64-0.45
EPS Diluted Before Nonrecurring Items-0.80-0.16-0.71-0.78-0.81-0.67-0.67-0.59-0.64-0.45
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Ventrus Biosciences stock analysis are:

  • Topline: A growing topline, as seen from the Ventrus Biosciences revenue chart, as is the case with Ventrus Biosciences indicates a growing business. One needs to compare the QoQ topline or sales growth of ASMB stock with its peers like CPXX stock and BTCA stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-16.25M for Ventrus Biosciences for 2018 Q1. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The ASMB financials along with Ventrus Biosciences historical stock prices provide a lot of details about the firm.

Ventrus Biosciences Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
81.07
Dividend Yield
0%